Comparison of botulinum neurotoxin products marketed in Europe and North America
Units are manufacturer specific and are not interchangeable.
| Botox/Vistabel | Dysport/Azzalure | Xeomin/Bocouture | Neurobloc/Myobloc | |
|---|---|---|---|---|
| Generic name | OnabotulinumtoxinA | AbobotulinumtoxinA | IncobotulinumtoxinA | RimabotulinumtoxinB |
| Manufacturer | Allergan (USA) | Ipsen Pharmaceuticals (France) | Merz Pharmaceuticals (Germany) | US WorldMeds (USA) |
| C. botulinum strain | Hall A-hyper | Hall A | Hall A (ATCC 3502) | Bean |
| Toxin type | A1 | A1 | A1 | B1 |
| MW | 900 kDa complex | MW not reported | 150 kDa | MW not reported |
| (PTCs) | (Yes) | (Yes) | None | (Yes) |
| Pharmaceutical form | Vacuum-dried powder for reconstitution | Freeze-dried powder for reconstitution | Freeze-dried powder for reconstitution | Ready-to-use solution |
| Shelf life | 2–8°C | 2–8°C | Room temperature | 2–8°C |
| 36 months | 24 months | 36 months | 24 months | |
| pH (reconstituted) | 7.4 | 7.4 | 7.4 | 5.6 |
| Excipients | In 100 U vial: | In 500 U vial: | In 100 U vial: | HSA 500 μg/ml |
| HSA 500 μg | HSA 125 μg | HSA 1000 μg | Succinate 10 mM | |
| NaCl (900 μg/vial) | Lactose (2.5 mg/vial) | Sucrose (4.7 mg/vial) | NaCl 100 mM | |
| Unit/vial | 100 U or 200 U Botox | 300 U or 500 U Dysport | 100 U or 200 U Xeomin | 2500 U/0.5 ml |
| 50 U Vistabel | 125 U Azzalure | 50 U Bocouture | 5000 U/1 ml | |
| 10,000 U/2 ml | ||||
| Protein load/vial | 5 ng/100 U | 4.35 ng/500 U | 0.44 ng/100 Ua | 55 ng/2500 U |
| Clinical activity in relation to Botox | 1 | 1:2–1:3 | 1 | 1:40–1:50 |
HSA, human serum albumin; PTC, progenitor toxin complex.
↵a Neurotoxin concentration measured by ELISA (Frevert, 2010).